Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction

Audio By Carbonatix

MILWAUKEE--(BUSINESS WIRE)--Sep 15, 2025--

The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi .

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Blueprint insiders received substantial benefits as part of change of control arrangements and certain insiders may have had conflicts of interests.

We are investigating whether the transaction offering documents may have contained materially misleading information and/or omissions.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250914104234/en/

CONTACT: Ademi & Fruchter LLP                                     

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

KEYWORD: UNITED STATES NORTH AMERICA WISCONSIN

INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL

SOURCE: Ademi & Fruchter LLP

Copyright Business Wire 2025.

PUB: 09/15/2025 01:10 AM/DISC: 09/15/2025 01:09 AM

http://www.businesswire.com/news/home/20250914104234/en